Third-generation anti-CD19 CAR T-cells demons

<ul>
<li>Adding a new CAR co-stimulatory domain (TLR2) to a conventional CD28-costimulated anti-CD19 CAR T-cell reduces cytokine release syndrome- and neurotoxicity-associated cytokines.</li>
<li>25 patients with relapsed or refractory B-cell non-Hodgkin lymphomas received CD28/TLR2 co-stimulated anti-CD19 CAR T-cells in a phase 1 dose escalation and expansion trial.</li>
<li>No severe CRS and no ICANS neurotoxicity of any grade occurred. Complete responses were seen at doses from 5 &times; 10⁴ to 1 &times; 10⁶ cells/kg.</li>
<li>Outpatient therapy and automated manufacture have been established in preparation for a phase 2 trial.</li>
</ul>

Related Keywords

San Diego ,California ,United States ,New Zealand ,Australia ,China ,Guangzhou ,Guangdong ,Wellington ,New Zealand General ,American ,Hunan Zhaotai ,Peter Lai ,Robert Weinkove ,Wellington Zhaotai Therapies ,Malaghan Institute Of Medical Research ,Thompson Family Foundation ,Wellington Zhaotai Therapies Limited Executive Director ,Zealand Ministry Of Business ,American Society Of Hematology ,Guangzhou Institute Of Biomedicine ,Malaghan Institute Clinical ,Health Research Council ,Method Of Research ,Malaghan Institute ,Health Research Council Of New Zealand ,Hunan Zhaotai Medical Group ,Hunan Zhaotai Medical Group Changsha ,Malaghan Institute Of Medical Research Wellington ,Clinical Practitioners Research Fellowship ,Medical Research ,Wellington Zhaotai Therapies Limited ,American Society ,Annual Meeting ,Malaghan Institute Clinical Director ,Principal Investigator Dr Robert ,Guangzhou Institute ,Hunan Zhaotai Medical ,Wellington Zhaotai Therapies Limited Executive ,Professor Carl June ,Blood Cancer New Zealand ,Health Research ,Zhaotai Therapies Limited ,Escalation Trial ,Toll Like Receptor ,Intracellular Domains ,Refractoryb Cell Non Hodgkin Lymphomas ,